# First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

> **NCT02729298** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 177 (actual)

## Conditions studied

- Advanced Solid Tumors
- EGFR Positive Non-small Cell Lung Cancer
- Colorectal Carcinoma
- Recurrent Ovarian Carcinoma
- BRAF-Mutated Melanoma

## Interventions

- **DRUG:** TP-0903

## Key facts

- **NCT ID:** NCT02729298
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-14
- **Primary completion:** 2022-06-29
- **Final completion:** 2022-06-29
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02729298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02729298, "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02729298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*